IPP Bureau
ABB India bags automation order for Reliance Life Sciences' biopharmaceutical facilities
By IPP Bureau - August 21, 2023
ABB India has secured an order from Reliance Life Sciences to deploy automation and control solutions for their new biosimilars and plasma proteins manufacturing facilities in Nashik, Maharashtra
Dr. Agarwal's Health Care raises US$80 mn from TPG and Temasek to expand network to 300 hospitals
By IPP Bureau - August 20, 2023
The company has new projects in development in Mumbai, Punjab, central and northern India, among others
Lupin receives approval from USFDA for Bromfenac Ophthalmic
By IPP Bureau - August 20, 2023
Bromfenac Ophthalmic Solution 0.09% (RLD Bromday) had estimated annual sales of USD 11 million in the U.S. (IQVIA MAT June 2023).
Lupin acquires Boehringer Ingelheim's brands Ondero and Ondero Met to expand diabetes portfolio in India
By IPP Bureau - August 19, 2023
This acquisition strengthens Lupin's commitment to providing superior treatment options for patients navigating the complexities of diabetes
Collaborative efforts and equitable access to diagnostic prevention needed to end TB: Dr. Mandaviya
By IPP Bureau - August 19, 2023
Combating the prevalent stigma against TB in the society, India has been committed to providing, enabling and patient-centric support to all, individuals suffering from TB
India's Medical Value sector projected to reach $ 13 billion by 2026: Dr Mandaviya
By IPP Bureau - August 18, 2023
Need to harmonize traditional and modern medicine to combat alarming health problems
Honeywell, Recipharm to speed development of inhalers
By IPP Bureau - August 18, 2023
Honeywell Solstice Air is a hydrofluoroolefin (HFO) propellant in clinical development today for pMDIs
BASF, Promega and Swiss TPH collaborate to drive research for malaria control
By IPP Bureau - August 18, 2023
Proteolysis Targeting Chimeras (PROTACs) technology as potential new method for mosquito-borne disease control
Aurobindo to launch HIV triple combination product for children living with HIV in low and middle-income countries
By IPP Bureau - August 17, 2023
Aurobindo's product is already filed with the Drugs Controller General of India (DCGI) and is expected to be approved soon
Lupin launches ‘Jeet’ to raise awareness of cardiovascular disease among patients
By IPP Bureau - August 17, 2023
Jeet will be a trusted partner in cardiovascular care
Glenmark Pharmaceuticals receives sANDA approval for Tacrolimus Ointment, 0.03%
By IPP Bureau - August 17, 2023
Glenmark's current portfolio consists of 184 products authorized for distribution in the U.S. marketplace
Lupin Launches Tiotropium Dry Powder for Inhaler for COPD in US
By IPP Bureau - August 17, 2023
Lupin actively contributes to alleviating the burden of COPD for patients across the nation
Cipla launches knowledge sharing platform ‘Ciplamed 2.0’
By IPP Bureau - August 16, 2023
CiplaMed 2.0 leverages advanced analytics and automation
SSI Strategy to acquires NDA Group partner to form global life sciences consultancy
By IPP Bureau - August 16, 2023
Combination creates an integrated provider of drug development and regulatory consulting services serving a complementary client base
